October 20, 2017 - 8:03 a.m.
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®
Printer Friendly Version 
October 18, 2017 - 5:44 p.m.
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Printer Friendly Version 
October 17, 2017 - 8:32 a.m.
Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
Printer Friendly Version 
October 16, 2017 - 8:01 a.m.
Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research
Printer Friendly Version 
October 12, 2017 - 4:02 p.m.
Gilead Sciences to Release Third Quarter 2017 Financial Results on Thursday, October 26, 2017
Printer Friendly Version 
October 04, 2017 - 8:02 a.m.
Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
Printer Friendly Version 
October 04, 2017 - 3:02 a.m.
Gilead Announces New License Agreement With the Medicines Patent Pool for Access to Bictegravir
Printer Friendly Version 
October 03, 2017 - 8:46 a.m.
Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
Printer Friendly Version 
October 03, 2017 - 8:01 a.m.
Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
Printer Friendly Version 
September 27, 2017 - 4:31 p.m.
Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire
Printer Friendly Version 
September 26, 2017 - 8:32 a.m.
Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
September 25, 2017 - 7:56 a.m.
China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection
Printer Friendly Version 
September 14, 2017 - 6:47 p.m.
Gilead Prices $3 Billion of Senior Unsecured Notes
Printer Friendly Version 
September 05, 2017 - 4:02 p.m.
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11
Printer Friendly Version 
September 01, 2017 - 9:01 a.m.
Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6
Printer Friendly Version 
August 28, 2017 - 4:00 a.m.
Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Printer Friendly Version 
August 10, 2017 - 4:02 p.m.
Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Printer Friendly Version 
August 01, 2017 - 4:02 p.m.
U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
Printer Friendly Version 
July 28, 2017 - 5:47 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
July 26, 2017 - 4:04 p.m.
Gilead Sciences Announces Third Quarter 2017 Dividend
Printer Friendly Version 
July 26, 2017 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2017 Financial Results
Printer Friendly Version 
July 24, 2017 - 5:07 a.m.
Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Printer Friendly Version 
July 18, 2017 - 1:36 p.m.
U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus
Printer Friendly Version 
July 13, 2017 - 6:59 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Printer Friendly Version 
July 12, 2017 - 5:01 p.m.
Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
Printer Friendly Version 
June 23, 2017 - 7:36 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
Printer Friendly Version 
June 12, 2017 - 8:17 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
June 01, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
Printer Friendly Version 
May 30, 2017 - 5:01 p.m.
Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
Printer Friendly Version 
May 30, 2017 - 8:31 a.m.
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
Printer Friendly Version 
May 04, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
Printer Friendly Version 
May 02, 2017 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2017 Dividend
Printer Friendly Version 
May 02, 2017 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2017 Financial Results
Printer Friendly Version 
April 21, 2017 - 12:01 p.m.
Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Printer Friendly Version 
April 21, 2017 - 4:31 a.m.
Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Printer Friendly Version 
April 20, 2017 - 12:01 p.m.
Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
Printer Friendly Version 
April 20, 2017 - 9:31 a.m.
Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Printer Friendly Version 
April 18, 2017 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
Printer Friendly Version 
April 07, 2017 - 10:11 a.m.
U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
Printer Friendly Version 
February 28, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
Printer Friendly Version 
February 14, 2017 - 7:01 p.m.
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Printer Friendly Version 
February 08, 2017 - 7:18 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Printer Friendly Version 
February 07, 2017 - 4:04 p.m.
Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Printer Friendly Version 
February 07, 2017 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Printer Friendly Version 
January 24, 2017 - 5:02 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
Printer Friendly Version 
January 20, 2017 - 5:49 a.m.
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Printer Friendly Version 
January 11, 2017 - 6:53 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
January 10, 2017 - 9:01 a.m.
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Printer Friendly Version 
January 03, 2017 - 4:31 p.m.
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Printer Friendly Version 
NASDAQ (US Dollar)
$81.21
 Stock is Down 0.38 (0.47%)
Data as of 10/20/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote